News Sentiment

NRIX sentiment intelligence

Nurix Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 63 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 23.06 Week of 10 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

72/100 classification confidence.

Company focus 54

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend active

-3.8% over one week, +36.0% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Nurix Therapeutics (NRIX) soars 16.4%: Is further upside left in the stock?

Market Reaction

Balanced read

64/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 72/100 classification
One-week reaction -3.8% Price reacting lower
Trend fit Trend active 36.0% over four weeks
Fair value 56.9% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 22
Neutral 32
Negative 9

Relevance

Why the article matched

Direct first
Direct company coverage 54
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
MarketBeat 9
Stock Titan 9
TradingView 5
simplywall.st 4
Moomoo 3
Seeking Alpha 3
Investing.com 2

Event Lens

What the news is about

Classified themes
Earnings 24
Market update 21
Analyst action 13
Deals and strategy 5

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 63
MarketBeat Direct company coverage

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Average Rating of "Moderate Buy" by Brokerages

Nurix Therapeutics, Inc. (NASDAQ:NRIX) has received an average rating of "Moderate Buy" from fourteen brokerages, with an average 12-month price target of $34.08. Several analysts have recently raised their price targets, despite the company missing its latest quarterly earnings

Tone
Positive 63/100
Event
Analyst action
Published
15 Jul 2026 06:13
Source
MarketBeat
MarketBeat Direct company coverage

Q3 EPS Estimates for Nurix Therapeutics Cut by HC Wainwright

HC Wainwright has reduced its Q3 2026 EPS estimate for Nurix Therapeutics (NASDAQ:NRIX) to ($0.69) per share, down from ($0.68), while maintaining a "Buy" rating and a $34 price target. This follows Nurix's reported wider-than-expected Q2 loss of ($0.81) per share and revenue of

Tone
Neutral 50/100
Event
Earnings
Published
14 Jul 2026 11:14
Source
MarketBeat
MarketBeat Direct company coverage

Sumitomo Mitsui Trust Group Inc. Sells 109,408 Shares of Nurix Therapeutics, Inc. $NRIX

Sumitomo Mitsui Trust Group Inc. reduced its stake in Nurix Therapeutics (NRIX) by 8.5% in the first quarter, selling 109,408 shares. This comes as Nurix Therapeutics reported a weaker-than-expected quarterly loss and revenue miss. Despite insider selling, Wall Street analysts ma

Tone
Negative 39/100
Event
Earnings
Published
14 Jul 2026 09:14
Source
MarketBeat
Investing.com Direct company coverage

Nurix stock price target raised to $34 by Mizuho on Roche deal

Mizuho has increased its price target for Nurix Therapeutics Inc. (NASDAQ:NRIX) shares to $34 from $30, maintaining an Outperform rating, following the company's transformative deal with Roche for bexdeg. The adjustment incorporates the financial benefits and expanded opportuniti

Tone
Positive 72/100
Event
Analyst action
Published
13 Jul 2026 20:14
Source
Investing.com
Moomoo Direct company coverage

Mizuho Raises Price Target on Nurix Therapeutics to $34 From $30, Keeps Outperform Rating

Mizuho has increased its price target for Nurix Therapeutics (NASDAQ: NRIX) to $34, up from the previous target of $30, while maintaining an Outperform rating on the stock. This adjustment suggests a positive outlook from the firm regarding Nurix Therapeutics' future performance

Tone
Positive 70/100
Event
Analyst action
Published
13 Jul 2026 13:11
Source
Moomoo
MarketBeat Direct company coverage

Mizuho Forecasts Strong Price Appreciation for Nurix Therapeutics (NASDAQ:NRIX) Stock

Mizuho has increased its price target for Nurix Therapeutics (NASDAQ:NRIX) from $30 to $34, maintaining an "outperform" rating, indicating a potential 47% upside. Despite this bullish outlook and a "Moderate Buy" consensus rating from analysts, Nurix recently reported wider-than-

Tone
Neutral 50/100
Event
Analyst action
Published
13 Jul 2026 13:10
Source
MarketBeat
MarketBeat Direct company coverage

55,138 Shares in Nurix Therapeutics, Inc. $NRIX Acquired by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd has acquired 55,138 shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) during the first quarter, valued at approximately $855,000, representing about 0.05% ownership. While Wall Street analysts generally have a "Moderate Buy" rating with a target price of

Tone
Neutral 50/100
Event
Analyst action
Published
13 Jul 2026 11:10
Source
MarketBeat
MarketBeat Direct company coverage

Nurix Therapeutics (NASDAQ:NRIX) Raised to Sell at Wall Street Zen

Wall Street Zen upgraded Nurix Therapeutics (NASDAQ:NRIX) from "strong sell" to "sell," while most other analysts maintain a "Moderate Buy" rating with an average target price of $33.77. The company's stock fell 6.6% to $23.06 following the report, despite trading above its movin

Tone
Neutral 50/100
Event
Analyst action
Published
12 Jul 2026 17:39
Source
MarketBeat
Webull Direct company coverage

NURIX THERAPEUTICS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $34 FROM $32

H.C. Wainwright has increased its target price for NURIX THERAPEUTICS, INC. shares from $32 to $34. The news, reported by Reuters, indicates a positive re-evaluation of the company's financial outlook by the analyst firm. This adjustment suggests a higher expected value for the c

Tone
Positive 72/100
Event
Analyst action
Published
12 Jul 2026 08:11
Source
Webull
TradingView Direct company coverage

Enterprise value to EBITDA forward of Nurix Therapeutics, Inc. – NASDAQ:NRIX

This article focuses on the enterprise value to EBITDA forward for Nurix Therapeutics, Inc. (NRIX) on the Nasdaq Stock Market. It provides a financial metric for the biotechnology company, indicating it was updated by humans and is available in English. The content is primarily a

Tone
Neutral 50/100
Event
Market update
Published
11 Jul 2026 00:10
Source
TradingView
TradingView Direct company coverage

Nurix Therapeutics, Inc. Stock 12‑Month Price Target Raised to $32.25, Implies 31% Upside

Nurix Therapeutics, Inc. (NRIX) has seen its average 12-month price target increase from $31.44 to $32.25, suggesting a potential 31% upside based on the July 9 closing price. This revised target is based on estimates from 16 analysts, with the consensus rating remaining a "Buy."

Tone
Positive 76/100
Event
Analyst action
Published
10 Jul 2026 16:40
Source
TradingView
Sahm Direct company coverage

Russell Growth Index Additions Could Be A Game Changer For Nurix Therapeutics (NRIX)

Nurix Therapeutics, Inc. (NRIX) was recently added to several Russell growth and small-cap indices, including the Russell 2000 Growth and Russell 2500 Growth. This inclusion is expected to increase the company's visibility among institutional investors and index funds. While this

Tone
Positive 64/100
Event
Market update
Published
10 Jul 2026 16:09
Source
Sahm
AlphaStreet Direct company coverage

Nurix Therapeutics Releases Q2 2026 Financial Results

Nurix Therapeutics reported a loss per share of $0.81 and revenue of $9.0M for Q2 2026, marking a significant revenue decline from the previous year. Despite widening losses due to investments in clinical development, Wall Street analysts maintain a positive outlook on the compan

Tone
Negative 39/100
Event
Earnings
Published
10 Jul 2026 15:40
Source
AlphaStreet
MarketBeat Direct company coverage

Nurix Therapeutics (NASDAQ:NRIX) Shares Down 8.6% After Earnings Miss

Nurix Therapeutics (NASDAQ:NRIX) saw its shares drop 8.6% after reporting a significant earnings and revenue miss for the quarter, with EPS at -$0.81 against an expected -$0.72 and revenue of $9.04 million versus a $15.29 million forecast. Despite these weak results, the company

Tone
Negative 41/100
Event
Earnings
Published
10 Jul 2026 14:40
Source
MarketBeat
MarketBeat Direct company coverage

Nurix Therapeutics (NASDAQ:NRIX) Price Target Raised to $33.00 at Royal Bank Of Canada

Royal Bank of Canada has increased its price target for Nurix Therapeutics (NASDAQ:NRIX) to $33.00, maintaining an "outperform" rating, which implies a potential upside of over 40%. This adjustment aligns with the overall constructive analyst sentiment, despite the company's rece

Tone
Positive 67/100
Event
Analyst action
Published
10 Jul 2026 13:40
Source
MarketBeat
Yahoo! Finance Canada Direct company coverage

Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Nurix Therapeutics announced its second-quarter 2026 financial results, highlighted by a significant global collaboration agreement with Roche for its BTK degrader, bexobrutideg. This partnership includes a potential $2.3 billion in payments, with a $700 million upfront payment,

Tone
Positive 73/100
Event
Earnings
Published
10 Jul 2026 07:41
Source
Yahoo! Finance Canada
FXStreet Direct company coverage

Nurix Therapeutics, Inc. (NRIX) reports Q2 loss, lags revenue estimates

Nurix Therapeutics, Inc. (NRIX) reported a Q2 loss of $0.81 per share, missing the Zacks Consensus Estimate of a $0.73 loss, and revenues of $9.04 million, significantly below the $44.06 million from the prior year and missing consensus by 36.76%. Despite the disappointing earnin

Tone
Neutral 50/100
Event
Earnings
Published
10 Jul 2026 06:40
Source
FXStreet
Moomoo Direct company coverage

Nurix Therapeutics Expects to Receive $700 M Upfront Payment From Roche in 3Q

Nurix Therapeutics anticipates receiving a $700 million upfront payment from Roche in the third quarter. This payment is part of a previously announced collaboration between the two companies. The collaboration aims to develop novel targeted protein degradation drugs.

Tone
Positive 92/100
Event
Earnings
Published
09 Jul 2026 20:39
Source
Moomoo
TradingView Direct company coverage

Enterprise value to EBIT forward of Nurix Therapeutics, Inc. – NASDAQ:NRIX

This article focuses on the enterprise value to EBIT forward ratio for Nurix Therapeutics, Inc. (NASDAQ: NRIX). It appears to be a financial data page from TradingView, displaying key financial metrics for the company. The content primarily lists navigation and footer information

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 20:39
Source
TradingView
MarketBeat Direct company coverage

Nurix Therapeutics (NASDAQ:NRIX) Releases Quarterly Earnings Results

Nurix Therapeutics (NASDAQ:NRIX) reported its quarterly earnings, missing analyst expectations for both EPS at ($0.81) versus ($0.73) and revenue at $9.04 million compared to $15.29 million. Despite the miss, the stock rose $0.38 to $24.69 on the day of the report, nearing its 12

Tone
Negative 37/100
Event
Earnings
Published
09 Jul 2026 20:39
Source
MarketBeat